Post-market monitoring of rapid diagnostic tests for COVID-19: confronting the pandemic:

Detalhes bibliográficos
Autor(a) principal: Coelho Adati, Marisa
Data de Publicação: 2021
Outros Autores: da Silva Ribeiro, Álvaro, de Assis Cirilo, Caique, Copello Vigo, Danielle, Custódio Deslandes do Passo, Danielle, Pires da Silva Macedo, Gabriella, Cristina Balthazar Guedes Borges, Helena, Roberto Niemeyer de Castro, José, Vieira Teixeira, Lívia, Melo da Silva, Marli, Cesar Moreno Guimarães, Paulo, Ismael Freitas de Maria, Raimundo, Malachini Maia, Renata, Machado do Passo, Roberto, Soares da Cunha, Rogério, Furtado de Mendonça, Valeria, Rosa Ribeiro, Yasmin, Moreira Marino Araújo, Ana Carolina, Gonçalves da Silva, Julierme, Cézar de Aquino, Nélio
Tipo de documento: Artigo
Idioma: por
eng
Título da fonte: Vigilância Sanitária em Debate
Texto Completo: https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1781
Resumo: Introduction: In December 2019, the  first group of patients with symptoms of atypical pneumonia was discovered in Wuhan, China. On January 7, 2020, the etiologic agent was identified; it was a new betacoronavirus, genetically similar to SARS-CoV-1, consisting of a simple RNA strand, an enveloped virus of 50-200nm in diameter, which was called SARS-CoV-2. Soon after, the disease was named COVID-19. On January 30, WHO declared a Public Health Emergency of International Importance due to the spread of the coronavirus. Tests for serological detection of IgM and IgG antibodies are those that provide an estimate of the immune response to SARS-CoV-2, highlighting the Rapid Diagnostic Tests (RDT), simple and accessible with a result within 5-30 minutes, based on sensitization of antigens/antibodies conjugated to colloidal gold capturing specific proteins present in the infected serum, plasma or blood. Objective: This work aims to show the analysis carried out with RDT for COVID-19 diagnosis in compliance with the current legislation from 02.04 to 18.08.2020. Method: In March of 2020, 25 serum/plasma samples were donated, without any identification. These samples were the remaining samples of tests performed on individuals with a confirmed diagnosis of SARS-CoV-2 infection by the RT-PCR technique from health services (National Institute of Infectious Diseases Evandro Chagas – INI and State Institute of the Brain Paulo Niemeyer – IEC) located in the metropolitan region of the state of Rio de Janeiro. The samples obtained in order to become a serological panel were stored at -20ºC until the moment of use. Simultaneously, a panel of samples with confirmed reactivity for IgM and IgG antibodies from COVID-19 was being made, throughout the pandemic and the samples used were evaluated against three Rapid Tests, of different antigenic compositions or different brands; two ELISA tests for IgM and IgG; two chemiluminescence tests and when applicable, a molecular test. In order to assess the specificity of the products sent, surplus donation plasma samples were selected, known to be negative for HIV, HTLV, hepatitis b and c, chagas and syphilis, collected between 2013 and 2014, in the southern regions of the country, period in which SARS-CoV-2 was nonexistent in the world. In addition to True Positive (VP) and True Negative (VN) samples, interfering serum or plasma samples with reactivity for HIV, HCV, HTLV, HBsAg, chagas disease, syphilis and dengue were also included in the evaluation. Results:  Out of 178 TR lots, 74.1%, 132 lots were from China and 25.9%, 46 TR lots were from Brazil; Germany; South Korea; Canada; USA; Singapore; Ireland and Switzerland. The analytical result showed that 57.0%, 101 TR lots obtained a Satisfactory result and 43%, 77 lots had Unsatisfactory results, when compared to the Sensitivity and Specificity values declared by the manufacturer, in the Instructions for Use. Conclusions:The results obtained show the need for constant monitoring of TRs for COVID-19 with the primary purpose of guaranteeing the quality of products sold in the country, one of the National Health Surveillance System pillars of action.  
id FIOCRUZ-9_fc4ac3bb1d4da7663eaeef211c3c6e6f
oai_identifier_str oai:ojs.visaemdebate.incqs.fiocruz.br:article/1781
network_acronym_str FIOCRUZ-9
network_name_str Vigilância Sanitária em Debate
repository_id_str
spelling Post-market monitoring of rapid diagnostic tests for COVID-19: confronting the pandemic: Monitoramento pós-mercado dos testes rápidos para COVID-19: enfrentamento da pandemia: COVID-19; SARS-CoV-2; Teste Rápido; Monitoramento da QualidadeCOVID-19; SARS-CoV-2; Rapid Diagnostic Test; Quality MonitoringIntroduction: In December 2019, the  first group of patients with symptoms of atypical pneumonia was discovered in Wuhan, China. On January 7, 2020, the etiologic agent was identified; it was a new betacoronavirus, genetically similar to SARS-CoV-1, consisting of a simple RNA strand, an enveloped virus of 50-200nm in diameter, which was called SARS-CoV-2. Soon after, the disease was named COVID-19. On January 30, WHO declared a Public Health Emergency of International Importance due to the spread of the coronavirus. Tests for serological detection of IgM and IgG antibodies are those that provide an estimate of the immune response to SARS-CoV-2, highlighting the Rapid Diagnostic Tests (RDT), simple and accessible with a result within 5-30 minutes, based on sensitization of antigens/antibodies conjugated to colloidal gold capturing specific proteins present in the infected serum, plasma or blood. Objective: This work aims to show the analysis carried out with RDT for COVID-19 diagnosis in compliance with the current legislation from 02.04 to 18.08.2020. Method: In March of 2020, 25 serum/plasma samples were donated, without any identification. These samples were the remaining samples of tests performed on individuals with a confirmed diagnosis of SARS-CoV-2 infection by the RT-PCR technique from health services (National Institute of Infectious Diseases Evandro Chagas – INI and State Institute of the Brain Paulo Niemeyer – IEC) located in the metropolitan region of the state of Rio de Janeiro. The samples obtained in order to become a serological panel were stored at -20ºC until the moment of use. Simultaneously, a panel of samples with confirmed reactivity for IgM and IgG antibodies from COVID-19 was being made, throughout the pandemic and the samples used were evaluated against three Rapid Tests, of different antigenic compositions or different brands; two ELISA tests for IgM and IgG; two chemiluminescence tests and when applicable, a molecular test. In order to assess the specificity of the products sent, surplus donation plasma samples were selected, known to be negative for HIV, HTLV, hepatitis b and c, chagas and syphilis, collected between 2013 and 2014, in the southern regions of the country, period in which SARS-CoV-2 was nonexistent in the world. In addition to True Positive (VP) and True Negative (VN) samples, interfering serum or plasma samples with reactivity for HIV, HCV, HTLV, HBsAg, chagas disease, syphilis and dengue were also included in the evaluation. Results:  Out of 178 TR lots, 74.1%, 132 lots were from China and 25.9%, 46 TR lots were from Brazil; Germany; South Korea; Canada; USA; Singapore; Ireland and Switzerland. The analytical result showed that 57.0%, 101 TR lots obtained a Satisfactory result and 43%, 77 lots had Unsatisfactory results, when compared to the Sensitivity and Specificity values declared by the manufacturer, in the Instructions for Use. Conclusions:The results obtained show the need for constant monitoring of TRs for COVID-19 with the primary purpose of guaranteeing the quality of products sold in the country, one of the National Health Surveillance System pillars of action.  Introdução: Em dezembro de 2019, foi descoberto na cidade de Wuhan, China, um primeiro grupo de pacientes com sintomas de uma pneumonia atípica. Em 7 de janeiro de 2020, o seu agente etiológico foi identificado: tratava-se de um novo betacoronavírus, geneticamente similar ao SARS-CoV-1, constituído defita simples de RNA, vírus envelopado de 50-200 nm de diâmetro designado como SARS-CoV-2, e a doença foi denominada COVID-19. Em 30 de janeiro, a Organização Mundial da Saúde declarou Emergência de Saúde Pública de Importância Internacional em razão da disseminação desse novo vírus. Os testes para detecção sorológica de anticorpos IgM e IgG fornecem uma estimativa da resposta imune ao SARS-CoV-2, com destaque para os Testes Rápidos (TR) que são simples e acessíveis fornecendo resultados em 5-30 min. Esses testes são sensibilizados com antígenos/anticorpos conjugados ao ouro coloidal, capturando proteínas específicas presentes no soro, plasma ou sangue de pacientes infectados. Objetivo: Demonstrar a análise efetuada nos TR para diagnóstico da COVID-19, em atendimento a legislação vigente, no período de 2 de abril a 18 de agosto de 2020. Método: Durante o mês de março de 2020, foram cedidas 25 amostras de soro/plasma, sem qualquer identificação, excedentes dos testes efetuados em indivíduos com diagnóstico confirmado de infecção pelo SARS-CoV-2 pela técnica de RT-PCR provenientes de serviços de saúde (InstitutoNacional de Infectologia Evandro Chagas – INI e Instituto Estadual do Cérebro Paulo Niemeyer – IEC) localizados na região metropolitana do estado do Rio de Janeiro. As amostras obtidas para a confecção de painel sorológico foram armazenadas a -20ºC até o momento do uso. Concomitantemente, um painel de amostras com reatividade confirmada para anticorpos IgM e IgG da COVID-19 foi sendo confeccionado ao longo da pandemia e as amostras utilizadas foram avaliadas frente a três TR, de diferentes composições antigênicas ou diferentes marcas; dois testes ELISA para IgM e IgG; dois testes de quimioluminescência e quando aplicável, um teste molecular. Para avaliação da especificidade dos produtos encaminhados, foram selecionadas amostras de plasma excedentes de doação, sabidamente negativas para HIV, HTLV, hepatite B e C, doença de chagas e sífilis coletadas nos anos de 2013 e 2014, na Região Sul do país, período no qual o SARS-CoV-2 era inexistente. Além de amostras Verdadeiro Positivas (VP) e Verdadeiro Negativas (VN), ainda foram incluídas na avaliação amostras de soro ou plasma interferentes com reatividade para HIV, HCV, HTLV, HBsAg, doença de chagas, sífilis e dengue. Resultados:  Dos 178 lotes de TR, 74,1% foram provenientes da China e 25,9%, do Brasil, da Alemanha, da Coreia do Sul, do Canadá, dos EUA, da Cingapura,da Irlanda e da Suíça. O resultado analítico demonstrou que 57,0% dos TR obtiveram resultados satisfatórios e 43,0%, resultados insatisfatórios, quando comparados aos valores de sensibilidade e especificidade declarados pelo fabricante na instrução de uso. Conclusões: Há necessidade de constante monitoramento dos TR para COVID-19, com finalidade precípua de garantir a qualidade dos produtos comercializados no país, um dos pilares das ações do Sistema Nacional de Vigilância Sanitária.Instituto Nacional de Controle de Qualidade em Saúde2021-08-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion"Peer-reviewed article""Artículo revisado por pares""Artigo avaliado pelos pares"application/pdfapplication/pdfhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/178110.22239/2317-269X.01781Health Surveillance under Debate: Society, Science & Technology ; Vol. 9 No. 3 (2021): August; 92-101Vigilancia en Salud en Debate: Sociedad, Ciencia y Tecnología; Vol. 9 Núm. 3 (2021): Agosto; 92-101Vigil Sanit Debate, Rio de Janeiro; v. 9 n. 3 (2021): Agosto; 92-1012317-269Xreponame:Vigilância Sanitária em Debateinstname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZporenghttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1781/1350https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1781/1409Copyright (c) 2021 Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia (Health Surveillance under Debate: Society, Science & Technology) – Visa em Debatehttps://creativecommons.org/licenses/by-nc/4.0info:eu-repo/semantics/openAccessCoelho Adati, Marisa da Silva Ribeiro, Álvaro de Assis Cirilo, Caique Copello Vigo, Danielle Custódio Deslandes do Passo, Danielle Pires da Silva Macedo, Gabriella Cristina Balthazar Guedes Borges, Helena Roberto Niemeyer de Castro, José Vieira Teixeira, Lívia Melo da Silva, Marli Cesar Moreno Guimarães, Paulo Ismael Freitas de Maria, Raimundo Malachini Maia, Renata Machado do Passo, Roberto Soares da Cunha, Rogério Furtado de Mendonça, Valeria Rosa Ribeiro, Yasmin Moreira Marino Araújo, Ana Carolina Gonçalves da Silva, Julierme Cézar de Aquino, Nélio 2023-06-27T15:13:38Zoai:ojs.visaemdebate.incqs.fiocruz.br:article/1781Revistahttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebatePUBhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/oaiincqs.visaemdebate@fiocruz.br || gisele.neves@fiocruz.br2317-269X2317-269Xopendoar:2023-06-27T15:13:38Vigilância Sanitária em Debate - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.none.fl_str_mv Post-market monitoring of rapid diagnostic tests for COVID-19: confronting the pandemic:
Monitoramento pós-mercado dos testes rápidos para COVID-19: enfrentamento da pandemia:
title Post-market monitoring of rapid diagnostic tests for COVID-19: confronting the pandemic:
spellingShingle Post-market monitoring of rapid diagnostic tests for COVID-19: confronting the pandemic:
Coelho Adati, Marisa
COVID-19; SARS-CoV-2; Teste Rápido; Monitoramento da Qualidade
COVID-19; SARS-CoV-2; Rapid Diagnostic Test; Quality Monitoring
title_short Post-market monitoring of rapid diagnostic tests for COVID-19: confronting the pandemic:
title_full Post-market monitoring of rapid diagnostic tests for COVID-19: confronting the pandemic:
title_fullStr Post-market monitoring of rapid diagnostic tests for COVID-19: confronting the pandemic:
title_full_unstemmed Post-market monitoring of rapid diagnostic tests for COVID-19: confronting the pandemic:
title_sort Post-market monitoring of rapid diagnostic tests for COVID-19: confronting the pandemic:
author Coelho Adati, Marisa
author_facet Coelho Adati, Marisa
da Silva Ribeiro, Álvaro
de Assis Cirilo, Caique
Copello Vigo, Danielle
Custódio Deslandes do Passo, Danielle
Pires da Silva Macedo, Gabriella
Cristina Balthazar Guedes Borges, Helena
Roberto Niemeyer de Castro, José
Vieira Teixeira, Lívia
Melo da Silva, Marli
Cesar Moreno Guimarães, Paulo
Ismael Freitas de Maria, Raimundo
Malachini Maia, Renata
Machado do Passo, Roberto
Soares da Cunha, Rogério
Furtado de Mendonça, Valeria
Rosa Ribeiro, Yasmin
Moreira Marino Araújo, Ana Carolina
Gonçalves da Silva, Julierme
Cézar de Aquino, Nélio
author_role author
author2 da Silva Ribeiro, Álvaro
de Assis Cirilo, Caique
Copello Vigo, Danielle
Custódio Deslandes do Passo, Danielle
Pires da Silva Macedo, Gabriella
Cristina Balthazar Guedes Borges, Helena
Roberto Niemeyer de Castro, José
Vieira Teixeira, Lívia
Melo da Silva, Marli
Cesar Moreno Guimarães, Paulo
Ismael Freitas de Maria, Raimundo
Malachini Maia, Renata
Machado do Passo, Roberto
Soares da Cunha, Rogério
Furtado de Mendonça, Valeria
Rosa Ribeiro, Yasmin
Moreira Marino Araújo, Ana Carolina
Gonçalves da Silva, Julierme
Cézar de Aquino, Nélio
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Coelho Adati, Marisa
da Silva Ribeiro, Álvaro
de Assis Cirilo, Caique
Copello Vigo, Danielle
Custódio Deslandes do Passo, Danielle
Pires da Silva Macedo, Gabriella
Cristina Balthazar Guedes Borges, Helena
Roberto Niemeyer de Castro, José
Vieira Teixeira, Lívia
Melo da Silva, Marli
Cesar Moreno Guimarães, Paulo
Ismael Freitas de Maria, Raimundo
Malachini Maia, Renata
Machado do Passo, Roberto
Soares da Cunha, Rogério
Furtado de Mendonça, Valeria
Rosa Ribeiro, Yasmin
Moreira Marino Araújo, Ana Carolina
Gonçalves da Silva, Julierme
Cézar de Aquino, Nélio
dc.subject.por.fl_str_mv COVID-19; SARS-CoV-2; Teste Rápido; Monitoramento da Qualidade
COVID-19; SARS-CoV-2; Rapid Diagnostic Test; Quality Monitoring
topic COVID-19; SARS-CoV-2; Teste Rápido; Monitoramento da Qualidade
COVID-19; SARS-CoV-2; Rapid Diagnostic Test; Quality Monitoring
description Introduction: In December 2019, the  first group of patients with symptoms of atypical pneumonia was discovered in Wuhan, China. On January 7, 2020, the etiologic agent was identified; it was a new betacoronavirus, genetically similar to SARS-CoV-1, consisting of a simple RNA strand, an enveloped virus of 50-200nm in diameter, which was called SARS-CoV-2. Soon after, the disease was named COVID-19. On January 30, WHO declared a Public Health Emergency of International Importance due to the spread of the coronavirus. Tests for serological detection of IgM and IgG antibodies are those that provide an estimate of the immune response to SARS-CoV-2, highlighting the Rapid Diagnostic Tests (RDT), simple and accessible with a result within 5-30 minutes, based on sensitization of antigens/antibodies conjugated to colloidal gold capturing specific proteins present in the infected serum, plasma or blood. Objective: This work aims to show the analysis carried out with RDT for COVID-19 diagnosis in compliance with the current legislation from 02.04 to 18.08.2020. Method: In March of 2020, 25 serum/plasma samples were donated, without any identification. These samples were the remaining samples of tests performed on individuals with a confirmed diagnosis of SARS-CoV-2 infection by the RT-PCR technique from health services (National Institute of Infectious Diseases Evandro Chagas – INI and State Institute of the Brain Paulo Niemeyer – IEC) located in the metropolitan region of the state of Rio de Janeiro. The samples obtained in order to become a serological panel were stored at -20ºC until the moment of use. Simultaneously, a panel of samples with confirmed reactivity for IgM and IgG antibodies from COVID-19 was being made, throughout the pandemic and the samples used were evaluated against three Rapid Tests, of different antigenic compositions or different brands; two ELISA tests for IgM and IgG; two chemiluminescence tests and when applicable, a molecular test. In order to assess the specificity of the products sent, surplus donation plasma samples were selected, known to be negative for HIV, HTLV, hepatitis b and c, chagas and syphilis, collected between 2013 and 2014, in the southern regions of the country, period in which SARS-CoV-2 was nonexistent in the world. In addition to True Positive (VP) and True Negative (VN) samples, interfering serum or plasma samples with reactivity for HIV, HCV, HTLV, HBsAg, chagas disease, syphilis and dengue were also included in the evaluation. Results:  Out of 178 TR lots, 74.1%, 132 lots were from China and 25.9%, 46 TR lots were from Brazil; Germany; South Korea; Canada; USA; Singapore; Ireland and Switzerland. The analytical result showed that 57.0%, 101 TR lots obtained a Satisfactory result and 43%, 77 lots had Unsatisfactory results, when compared to the Sensitivity and Specificity values declared by the manufacturer, in the Instructions for Use. Conclusions:The results obtained show the need for constant monitoring of TRs for COVID-19 with the primary purpose of guaranteeing the quality of products sold in the country, one of the National Health Surveillance System pillars of action.  
publishDate 2021
dc.date.none.fl_str_mv 2021-08-31
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
"Peer-reviewed article"
"Artículo revisado por pares"
"Artigo avaliado pelos pares"
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1781
10.22239/2317-269X.01781
url https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1781
identifier_str_mv 10.22239/2317-269X.01781
dc.language.iso.fl_str_mv por
eng
language por
eng
dc.relation.none.fl_str_mv https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1781/1350
https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/1781/1409
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by-nc/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Instituto Nacional de Controle de Qualidade em Saúde
publisher.none.fl_str_mv Instituto Nacional de Controle de Qualidade em Saúde
dc.source.none.fl_str_mv Health Surveillance under Debate: Society, Science & Technology ; Vol. 9 No. 3 (2021): August; 92-101
Vigilancia en Salud en Debate: Sociedad, Ciencia y Tecnología; Vol. 9 Núm. 3 (2021): Agosto; 92-101
Vigil Sanit Debate, Rio de Janeiro; v. 9 n. 3 (2021): Agosto; 92-101
2317-269X
reponame:Vigilância Sanitária em Debate
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Vigilância Sanitária em Debate
collection Vigilância Sanitária em Debate
repository.name.fl_str_mv Vigilância Sanitária em Debate - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv incqs.visaemdebate@fiocruz.br || gisele.neves@fiocruz.br
_version_ 1797042046489329664